Parents of deceased Botox patient hit Allergan with lawsuit; FDA approves Zytiga label update;

@FiercePharma: ICYMI yesterday: Merck's Frazier joins top-paid pharma CEOs with a $25M package. Article | Follow @FiercePharma

@EricPFierce: Sounds like Walgreens would like to buy into another drug distributor like AmerisourceBergen. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: The coming generics threat to Pfizer's Viagra brand just got scarier. FiercePharmaMarketing report | Follow @CarlyHFierce

> The parents of a Vermont woman who died last year have sued Botox-maker Allergan ($AGN)--now part of Actavis ($ACT)--saying treatment of her cerebral palsy with the drug helped lead to her death and that the company didn't properly warn of risks. More

> Ireland's pharmaceutical industry has been boosted by a stream of significant new investments in recent years, according to a new report. More

> The FDA has approved a label update for Johnson & Johnson's ($JNJ) Zytiga that includes overall survival results in chemotherapy-naive patients with metastatic castration-resistant prostate cancer. Release

> FDA reviewers have recommended that the agency approve The Medicines Company's ($MDCO) once-rejected blood clot preventer. Report

> Santhera Pharmaceuticals may market a degenerative muscular disease drug on its own in the U.S. to secure a bigger share of revenue and longer patent protection. Report

Medical Device News

@FierceMedDev: EarlySense nabs Mitsui as Japan partner, investor and ups financing to $25M. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: Medtronic joins St. Jude in leadless pacemaker market thanks to CE mark. Report | Follow @VarunSaxena2

@EmilyWFierce: Visual app acts as a "cheat sheet" for docs looking for a quick diagnosis. Wired story | Follow @EmilyWFierce

> Startup raises $4M for sterilization with vaporized hydrogen peroxide. More

> Baxter expanding its manufacturing plant in Arkansas amid preparations to spin off pharma biz. Story

Biotech News

@FierceBiotech: Galapagos' closely-watched rheumatoid arthritis drug filgotinib scores in PhIIb. Report | Follow @FierceBiotech

@JohnCFierce: Meanwhile, back in biotech boomland, Aduro prices at $17 a share. Over the range
$ADRO. Reuters story | Follow @JohnCFierce

> Bayer pours $100M into Bay Area R&D with eyes on hemophilia. Report

> Aduro pulls off a $119M IPO to fund its immuno-oncology pipeline. Story

> Dominant VC NEA gathers $3B, preps for another wave of biotech rounds. Article

Pharma Marketing News

> Eisai rejig means sales-force downsizing at a critical moment for Arena's Belviq. More

> Tech it out: Pfizer, AARP and UnitedHealthcare push innovation. Report

> J&J's Invokana fends off new SGLT2 rivals to hit $278M in Q1. More

> DTC ad viewers really do ask their doctors about new meds, survey finds. Story

> The coming generics threat to Pfizer's Viagra brand just got scarier. Article

Biotech Research News

> Focused on cell signaling, CHOP team preps for human mitochondrial drug study. Report

> UCLA team packs large cargo into cells. Item

> Scripps Parkinson's study points to a key enzyme as a potential drug target. More

> MIT team works on amping up a new approach to cancer immunotherapies. Story

> Chicago project highlights effects of an ancient Chinese cardio remedy. Article

Diagnostics News

> GE and Veracyte team up for disease diagnostic research collaboration. Item

> NIH awards $11M to develop tests for drug-resistant bacteria. Story

> FDA announces LuSys Labs' recall of its unapproved Ebola diagnostic. More

> Roche grabs CAPP Medical to gain ground in cancer Dx. News

> Biocartis joins forces with Microbiome for quick sepsis test. Article

And Finally... Australia is cutting off government welfare for anti-vaxxers. More